Managing refractory meningioma presents a major challenge for multidisciplinary neuro-oncology teams worldwide. Although surgical resection and focused radiotherapy remain primary interventions, tumors frequently recur and exhibit aggressive clinical progression. When standard local interventions fail, clinicians explore recurrent meningioma salvage therapies to achieve disease stabilization and improve quality of life. Historically, systematic clinical trial data evaluating systemic agents in this space remained heterogeneous and poorly defined. To resolve this critical evidence gap, the Response Assessment in Neuro-Oncology (RANO) meningioma working group conducted an extensive systematic review and meta-analysis. This landmark study establishes robust historical baselines, evaluates contemporary drug classes, and establishes pragmatic benchmarks for future clinical trials.

Clinical Dilemma in Refractory Meningioma Management

Meningiomas represent the most common primary intracranial neoplasms encountered in adult clinical practice. While clinicians manage the majority of benign cases successfully with gross total resection, recurrent cases present severe clinical dilemmas. Higher-grade lesions, such as atypical and anaplastic tumors, frequently recur despite repeat surgical resections and adjuvant radiation therapy. Furthermore, recurrent tumors often invade critical neurovascular structures and dural sinuses, which substantially elevates surgical morbidity.

In such refractory scenarios, repeat irradiation carries significant risks of radionecrosis and permanent neurological deficits. Consequently, medical oncologists and neurosurgeons must increasingly rely on medical salvage interventions to halt intracranial disease progression. However, international treatment guidelines, including those from the European Association of Neuro-Oncology and the National Comprehensive Cancer Network, lack standard, approved systemic agents for meningioma. Clinicians frequently test diverse off-label options, such as anti-angiogenic agents, somatostatin receptor agonists, and receptor tyrosine kinase inhibitors. Therefore, systematically evaluating the historical efficacy of these diverse systemic regimens provides an essential foundation for optimizing future clinical protocols.

Meta-Analysis Findings for Recurrent Meningioma Salvage Therapies

The RANO working group conducted a comprehensive systematic review across major medical databases, including PubMed, ClinicalTrials.gov, and ASCO publications. The investigators evaluated progression-free survival at six months and one year as primary objective endpoints. Using random-effects models to pool survival data, the researchers analyzed outcomes across distinct tumor grades and therapeutic classes.

For recurrent World Health Organization grade 1 meningiomas, the pooled six-month progression-free survival rate reached 43.6%, while the one-year rate was 21.7%. Conversely, patients with aggressive grade 2 and grade 3 meningiomas achieved a pooled six-month progression-free survival rate of 38.0%. These pooled data highlight the aggressive natural biology and treatment resistance of high-grade lesions. Moreover, the meta-analysis revealed marked heterogeneity among older cytotoxic chemotherapy trials, which historically demonstrated minimal anti-tumor activity. In contrast, modern recurrent meningioma salvage therapies demonstrated progressively improved disease control rates. Consequently, these pooled statistics establish a reliable historical control cohort, enabling investigators to distinguish true pharmacological efficacy from baseline disease progression in upcoming trials.

Role of Targeted Therapy and Immunotherapy Modalities

Recent advances in molecular profiling have transformed our understanding of meningioma genetics, uncovering actionable alterations such as NF2, AKT1, TRAF7, SMO, and KLF4 mutations. Consequently, targeted therapeutics and biological agents have become central to contemporary clinical investigation. The RANO meta-analysis clearly demonstrates superior outcomes when clinicians employ targeted systemic therapies compared to traditional cytotoxic agents.

Specifically, in patients with recurrent grade 1 meningiomas, targeted therapies achieved a remarkable six-month progression-free survival rate of 62.0% and a one-year rate of 49.0%. For aggressive grade 2 and grade 3 tumors, targeted agents produced a six-month progression-free survival rate of 42.1%. Furthermore, immune checkpoint inhibitors yielded an encouraging six-month progression-free survival rate of 46.0% in high-grade cohorts. Anti-angiogenic agents targeting vascular endothelial growth factor pathways, such as bevacizumab and sunitinib, also demonstrated meaningful clinical stabilization. In addition, somatostatin receptor-targeted agents, including peptide receptor radionuclide therapies, showed promising activity in receptor-positive refractory tumors. Thus, precision oncology strategies represent the most promising pathway toward improving clinical outcomes in difficult-to-treat patient populations.

Establishing New RANO Efficacy Benchmarks

A major limitation of previous neuro-oncology trials was the absence of standardized historical benchmarks to evaluate single-arm phase 2 clinical studies. Without defined statistical thresholds, interpreting whether a novel systemic drug offered genuine clinical benefit remained subjective and inconsistent. To address this persistent problem, the RANO working group proposed clear rates of probable interest for future clinical trial design.

Based on their pooled analyses, the expert panel established specific progression-free survival benchmarks that future investigational drugs must exceed to demonstrate meaningful efficacy. For recurrent grade 1 meningiomas, future clinical trials should target a six-month progression-free survival rate of 67% and a one-year rate of 54%. For recurrent grade 2 and grade 3 tumors, the new benchmark requires a six-month progression-free survival rate of 49%. These elevated statistical thresholds ensure that future therapeutic candidates demonstrate superiority over historical systemic therapies. Furthermore, adopting these standardized criteria will streamline drug screening, reduce investigative bias, and accelerate the development of truly transformative treatments for patients with refractory disease.

Implications for Neuro-Oncology Clinical Practice and Research

The benchmarks established by the RANO meningioma group provide vital guidance for clinicians and clinical researchers across global neuro-oncology communities. In daily clinical practice, these findings emphasize that traditional cytotoxic chemotherapies offer very limited benefit for recurrent meningiomas. Instead, clinicians should prioritize comprehensive molecular diagnostics and next-generation sequencing to identify actionable therapeutic targets whenever feasible.

Moreover, multidisciplinary tumor boards should consider enrolling refractory patients into well-designed clinical trials that incorporate these new RANO efficacy criteria. For neuro-oncologists practicing in diverse clinical settings, including tertiary cancer centres in India, these benchmarks offer a structured framework to evaluate off-label treatments rationally. Clinicians can better counsel patients regarding realistic expectations when using anti-angiogenic agents, targeted small molecules, or somatostatin analogues. Furthermore, these updated standards encourage international cooperative groups to design molecularly stratified clinical trials. Ultimately, standardizing trial endpoints will accelerate regulatory approvals and bring effective precision medicines into routine neuro-oncology practice.

Frequently Asked Questions

What are the new RANO trial benchmarks for recurrent meningioma salvage therapies?

The RANO working group established efficacy benchmarks of 67% six-month and 54% one-year progression-free survival for recurrent grade 1 meningiomas. For recurrent grade 2 and 3 meningiomas, the benchmark is set at a 49% six-month progression-free survival rate to demonstrate meaningful investigational drug activity.

Why do traditional cytotoxic chemotherapies show poor outcomes in recurrent meningiomas?

Traditional cytotoxic agents fail to provide substantial clinical benefit because meningiomas possess low mitotic indices and intrinsic chemoresistance mechanisms. Consequently, cytotoxic drugs produce minimal anti-tumor activity while causing systemic toxicities. Modern treatment strategies therefore prioritize targeted biological inhibitors and immunotherapy over conventional chemotherapeutic regimens.

Which systemic therapies currently demonstrate the highest disease control in refractory meningioma?

Targeted therapies and immunotherapies demonstrate the highest clinical disease control. Specifically, anti-angiogenic agents like bevacizumab, somatostatin receptor-targeted therapies, and molecularly targeted small-molecule inhibitors achieve superior progression-free survival rates compared to conventional cytotoxic regimens in both low-grade and high-grade recurrent meningioma cohorts.

Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice. Healthcare professionals should make diagnostic and therapeutic decisions based on their independent clinical judgment, individual patient evaluation, and relevant medical facts. Refer to the latest local and national guidelines for clinical practice.

References

1. Kotecha R et al. Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design. Neuro Oncol. 2025 Sep 08. doi: 10.1093/neuonc/noaf009. PMID: 39807850.
2. Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncology. 2021;23(11):1821-1834. doi:10.1093/neuonc/noab150.
3. Wen PY, Weller M, Lee EQ, et al. Neurological Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurological function for clinical trials in brain tumors. Lancet Oncol. 2017;18(10):e623-e634. doi:10.1016/S1470-2045(17)30559-7.
4. Huang RY, Bi WL, Weller M, et al. Proposed response assessment and clinical trial design in meningioma (RANO). Neuro-Oncology. 2019;21(1):26-36. doi:10.1093/neuonc/noy137.